Recurrent Glioblastoma Multiforme Treatment Market 2021 Snapshot | Industry Predict a Long-Term Growth at 6.14% CAGR by Revenue US$ 560.9 million by 2028 | Coherent Market Insights

Recurrent Glioblastoma Multiforme Treatment Market, by Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Glioblastoma is a form of brain tumor that develops from glial or supporting brain tissue, often known as glioma. Glioblastoma multiforme (shortened as GBM) is a severe malignant brain tumor with a bad prognosis. The commercially available therapy approach for this disease confronts several hurdles, such as drug concentrations at the tumor site being limited due to the crossing of the blood-brain-barrier. Key players are actively engaged in R&D activities to discover and launch novel medications for the treatment of such diseases.

Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/682

According to a 2018 study published in the Journal of Neurosurgery, advances in the past several decades have not appreciably enhanced the lifespan of individuals with recurrent glioblastoma multiforme (GBM) disease. The magazine also includes summaries of recent novel endeavors in basic and clinical research. According to these brief discussions by medical experts, it is noted that a subset of recurrent GBM patients could benefit from aggressive treatment efforts, despite the fact that this disease is still potentially lethal.

The growing prevalence of brain tumors is expected to fuel the global recurrent glioblastoma multiforme treatment market growth over the forecast period. GBM is the worst type of brain cancer, accounting for 45 % of all malignant brain tumors, according to the National Foundation for Cancer Research. Moreover, according to a National Brain Tumor Society report, around 10% of individuals with brain tumors are at a very high risk of getting glioblastomas.

Recurrent Glioblastoma Multiforme Treatment Market – Impact of Coronavirus (Covid-19) Pandemic

The unexpected global outbreak of COVID-19 has severely disrupted the recurrent glioblastoma multiforme and other diseases treatment. Individuals are unable to visit health and surgery centers for health monitoring, chemotherapy, and radiotherapy. This outbreak has also had an influence on the worldwide pharmaceutical supply chain, making treatment more difficult to procure and available for patients with recurrent glioblastoma multiforme.

The comprehensive edition of the research will contain the impact of COVID-19 as well as the expected changes in the industry’s future perspective, taking into consideration the social, economic, technological, and political elements.

The global recurrent glioblastoma multiforme treatment market was worth US$ 369.6 Mn in 2020, growing at a CAGR of 6.14 % over the forecast period 2020-2027.

New drug launches and approvals for treating GBM are expected to drive the global recurrent glioblastoma multiforme treatment market growth over the forecast period.

Pfizer announced ‘Zirabev,’ a bevacizumab biosimilar of Avastin, in the U.S. in January 2020, for the treatment of recurrent glioblastoma multiforme. The U.S. Food and Drug Administration approved the biosimilar in June 2019 to treat recurrent or metastatic NSCLC, metastatic or recurrent cervical cancer, metastatic renal cell carcinoma, metastatic colorectal cancer, and recurrent glioblastoma multiforme.

Moreover, major market players are collaborating and forming joint ventures to make and market new medications to enhance their position in the global recurrent glioblastoma multiforme therapy market over the forecast period. For instance, DelMar Pharmaceuticals, signed a partnership agreement with PRA Health Sciences in May 2017 to perform phase 3 clinical trials of VAL-083 for the recurrent GBM treatment. PRA Health Sciences is a contract research organization that offers biotechnology and pharmaceutical companies subcontracted clinical development services.

The U.S. Food and Drug Administration approved Samsung’s BLA application for SB8 bevacizumab, a biosimilar to Avastin, in November 2019. If approved, Merck & Co., Inc., will market this biosimilar in the U.S. Merck & Co. is a partner of Samsung for its infliximab biosimilar – Renflexis.

Recurrent Glioblastoma Multiforme Treatment Market Restraints

Furthermore, the lack of adequate treatments and their failure to successfully control tumor recurrence are the key factors that are expected to hinder the global recurrent glioblastoma multiforme treatment market growth over the forecast period.

Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/682

Recurrent Glioblastoma Multiforme Treatment Market – Regional Analysis

Due to the presence of significant market players, rising healthcare awareness, and U.S. food and drug administration approvals for new medications in the market, in 2019 North America held the dominant position in the global recurrent glioblastoma multiforme treatment market. For instance, Denovo Biopharma, a biotech company based in San Diego received U.S. Food and Drug Administration approval in October 2019 for its phase 2b clinical trial assessing an analytical combination therapy for treating recently diagnosed glioblastoma multiforme individuals. The DB102 therapy has been cleared for trials to assess its efficacy in conjunction with radiation and temozolomide (Temodar).

Furthermore, key players in the North America market are adopting R&D and partnership strategies, which are fueling the global recurrent glioblastoma multiforme treatment market growth. For instance, UCLA and Advaxix in October 2019 announced a research agreement for glioblastoma multiforme immunotherapy solutions. The goal of this agreement for Advaxix was to undertake preclinical tests on UCLA’s Lm technology in mice tumor models of GBM.

Moreover, Asia Pacific businesses are involved in research and development for innovative GBM treatments. Companies such as Kazia Therapeutics, Samsung Bioepis, and others are working on new medications for the recurrent glioblastoma multiforme treatment. For instance, Kazia Therapeutics, an Australian biopharma company, began phase II clinical trials for its medication, GDC-0084, in the U.S. in March 2018. Furthermore, a new vaccine, Rindopepimut, is nearing completion in India and Australia for first-line GBM treatment.

Recurrent Glioblastoma Multiforme Treatment Market – Competitive Landscape

Some of the major players in the global recurrent glioblastoma multiforme treatment market are Genzyme Corporation, Cortice Biosciences, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Eli Lilly and Company, Eli Lilly and Company, ImmunoCellular Therapeutics, Ltd., AstraZeneca, Celldex Therapeutics, Inc., AngioChem, Inc., GW Pharmaceuticals Plc., Boehringer Ingelheim GmbH, F. Hoffman-La Roche, Ltd., Coherus BioSciences, Inc., Cantex Pharmaceuticals, Inc., ERC Belgium SA, Merck & Co., Inc., Boston Biomedical, Inc., GenSpera, Inc., Cavion LLC, Vascular Biogeneics, GlaxoSmithKline plc., and Eisai, EnGeneIC Ltd.

Reasons to Purchase this Report

• Current and future of global Recurrent Glioblastoma Multiforme Treatment Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations

Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/682

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Overview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Treatment
     • Market Snippet, By Type
     • Market Snippet, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Technological Advancements in Recurrent Glioblastoma Multiforme Treatment
   • Key Developments
   • Acquisition, Collaborations & Partnerships
   • Epidemiology
   • Reimbursement Analysis
   • Pipeline Analysis
   • Pricing Analysis
   • Treatment Algorithm
4. Global Recurrent Glioblastoma Multiforme Treatment Market, Impact of Coronavirus (Covid-19) Pandemic
   • Pre-COVID Situation
   • Post-COVID Demand
   • Need for Recurrent Glioblastoma Multiforme Treatment
   • Recommendations and Guidelines by Regulatory Bodies
5. Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment, 2016 – 2027, (US$ Million)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Oral Medications
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Radiosensitizers
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Nitrosoureas Drugs
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Chemotherapy
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
6. Global Recurrent Glioblastoma Multiforme Treatment Market, By Type, 2016 – 2027, (US$ Million)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017 – 2027
     • Segment Trends
   • Grade II or Grade III
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Grade IV
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
   • Others
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
7. Global Recurrent Glioblastoma Multiforme Treatment Market, By Region, 2016 – 2027, (US$ Million)
   • Introduction
     • Market Share Analysis, By Region, 2020 and 2027(%)
     • Y-o-Y Growth Analysis, By Region, 2017 –2027
     • Regional Trends
   • North America
     • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
       • U.K.
       • Germany
       • Italy
       • France
       • Spain
       • Russia
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
       • China
       • Japan
       • India
       • ASEAN
       • Australia
       • South Korea
       • Rest of Asia Pacific
   • Latin America
     • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
       • Brazil
       • Mexico
       • Argentina
       • Rest of Latin America
   • Africa
     • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
       • North Africa
       • Central Africa
       • South Africa
   • Middle East
     • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
     • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
       • GCC
       • Israel
       • Rest of Middle East